Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-010330 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Xuewei Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We have read with great interest the recent publication entitled “Pretreatment CT-based Machine Learning Radiomics Model Predicts Response in Unresectable Hepatocellular Carcinoma Treated with Lenvatinib plus PD-1 Inhibitors and Interventional Therapy” by Hua et al.1 Although lenvatinib combined with programmed cell death protein-1 inhibitors and interventional (LPI) therapy can be used as primary treatment options, some patients may still be non-responsive to LPI therapy and experience significant adverse events. However, there are no reliable and accurate biomarkers to predict a patient’s response to LPI therapy. To this end, this study developed and validated a radiomics-based machine learning model to non-invasively predict the efficacy of this triple therapy, and to perform risk stratification in those patients with unresectable hepatocellular carcinoma (HCC). The radiomic model performed similarly to the clinical-radiomics model, suggesting that clinical factors failed to produce incremental value to the radiomics model. It is encouraging to see an article focused on developing treatment response prediction models for targeted patients with HCC. This study offers valuable insights for clinicians on how to use radiomics for making clinical decisions and tailoring individualized treatments for patients with unresectable HCC. While the study’s results are promising, several issues warrant further clarification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
- Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China xld_Jane_Eyre@126.com.
ORCID-Profile: Xuewei Wu, Jingjing You, Shuixing Zhang, Bin Zhang
Zitieren
APA
Wu, X., You, J., Zhang, S., & Zhang, B. (2024). Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010330
Vancouver
Wu X, You J, Zhang S, Zhang B. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-010330
BibTeX
@article{Wu2024,
author = {Wu, Xuewei and You, Jingjing and Zhang, Shuixing and Zhang, Bin},
title = {Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-010330}
}
EUVIMED